 |
인쇄하기
취소
|
Hanmi signs deal to transfer platform technology to U.S. drug maker
Hanmi Pharmaceutical Co. signed Friday a $34 million deal with New York based Kinex Pharmaceuticals to transfer its ORASCOVERY, the platform technology that enables the development of orally available drugs.
Hanmi said that, under the agreement, it will transfer its ORASCOVERY based technology of Oraxol, the orally administered form of Paclitaxel and other injectable cytotoxics, to Kinex and...
Hanmi said that, under the agreement, it will transfer its ORASCOVERY based technology of Oraxol, the orally administered form of Paclitaxel and other injectable cytotoxics, to Kinex and...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.